Represents one of the largest cell culture biomanufacturing sites in North America, which will employ 1,400 people by 2031
The new site will increase Syngene's total single-use bioreactor capacity to 50,000L
Overall investment in the US facility is estimated around US$50 million
The new facility uses the latest mammalian systems and single-use technology, including a production line with eight 2,000 L bioreactors
He will lead the final stages of work to commission the 54,000-square-foot facility and then lead ongoing operations at the site
India's healthcare sector anticipates telemedicine reaching US$ 5.4 billion by 2025, with AI growing at 45% by 2024 and Healthtech jobs increasing 15-20%
Executes the first project for developing and manufacturing a novel anticancer mAb
Lonza plans to invest approximately CHF 500 million to upgrade the facility
Development services for gene and cell therapies is planned to begin first in 2025
Biologics manufacturing to expand the Aragen platform by offering “gene to GMP” solution
Subscribe To Our Newsletter & Stay Updated
